These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 11366283

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Experimental drug quickly suppresses HIV.
    AIDS Read; 2005 Apr; 15(4):150. PubMed ID: 15844233
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Is it time to rethink the expanded-access programs for HIV infection?
    Amorosa V, Tebas P.
    J Infect Dis; 2007 Oct 01; 196(7):974-7. PubMed ID: 17763316
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Opinion paper. Resistance to new anti-HIV agents: problems in the pathway of drug registration.
    Dalmau D, Klimkait T, Telenti A.
    Antivir Ther; 2005 Oct 01; 10(7):867-72. PubMed ID: 16312184
    [Abstract] [Full Text] [Related]

  • 9. 100th HIV/AIDS antiretroviral drug approved by PEPFAR.
    AIDS Patient Care STDS; 2009 Nov 01; 23(11):988-9. PubMed ID: 19938372
    [No Abstract] [Full Text] [Related]

  • 10. Expanded and early access and patient assistance programs for other experimental drugs from their manufacturers.
    Crit Path AIDS Proj; 1998 Nov 01; (No 33):43-64. PubMed ID: 11366373
    [Abstract] [Full Text] [Related]

  • 11. AIDS treatment. Drugmakers test restrictions on generics in U.S. programs.
    Cohen J.
    Science; 2004 Oct 08; 306(5694):213. PubMed ID: 15472049
    [No Abstract] [Full Text] [Related]

  • 12. FDA community meeting May 16: clinical trials and viral load. Food and Drug Administration.
    AIDS Treat News; 1997 May 01; (No 270):3. PubMed ID: 11364324
    [Abstract] [Full Text] [Related]

  • 13. Generic nucleoside approved.
    AIDS Patient Care STDS; 2005 Aug 01; 19(8):540. PubMed ID: 16163787
    [No Abstract] [Full Text] [Related]

  • 14. On approval.
    Huff B.
    GMHC Treat Issues; 2001 Oct 01; 15(10):5-8. PubMed ID: 11727570
    [No Abstract] [Full Text] [Related]

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Oct 01; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 16. Emerging drugs in the fight against HIV disease.
    Rosenthal E.
    HRSA Careaction; 2003 Feb 01; ():1-8. PubMed ID: 12739497
    [No Abstract] [Full Text] [Related]

  • 17. [New drugs, new obstacles in the fight against HIV].
    Fonseca MS.
    Sidahora; 1996 Feb 01; ():13-4. PubMed ID: 11364289
    [Abstract] [Full Text] [Related]

  • 18. Tenofovir: Gilead applies for approval; expanded access liberalized.
    Gilden D.
    AIDS Treat News; 2001 May 11; (364):2-3, 1. PubMed ID: 11569959
    [Abstract] [Full Text] [Related]

  • 19. FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James.
    Feigal D.
    AIDS Treat News; 1997 Jun 20; (No 273):1-5. PubMed ID: 11364399
    [Abstract] [Full Text] [Related]

  • 20. FDA notifications. Reyataz is approved for HIV treatment.
    AIDS Alert; 2003 Sep 20; 18(9):119-20. PubMed ID: 14686309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.